 | • レポートコード：D0-MOR-AP0674 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、ヒドロキシジンイミンの世界市場について調査・分析した資料で、ヒドロキシジンイミンの市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The global hydroxyzine imine market is anticipated to witness a CAGR of nearly 5.1% during the forecast period. The increasing population with allergic reactions coupled with the geriatric population is among the key trends expected to trigger market growth. As per the Drug Database Statistic, hydroxyzine is among the top 100 brands and around 8 million prescriptions were given in the United States (2017), which is also boosting the market growth. Moreover, technological advancements with increasing investments in R&D for developing novel therapeutic drugs will also propel market growth. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth. However, side effects associated with this drug such as dizziness, skin rashes, and severe seizure may restrain the growth of the market.
Key Market Trends
Capsules Segment is Expected to Hold Significant Market Share in the Hydroxyzine imine Market
Capsules segment is expected to contribute significant market share attributing to ease of administration, ease of usage, easy availability and widely used in allergic reaction patients. Moreover, as hydroxyzine imine attenuates activity in the central nervous system, these properties helps hydroxyzine imine to treat anxiety associated with psychoneurosis. This is leading to adoptions of hydroxyzine imine capsules for several advantages such as stability in different ranges of temperature & humidity, physical stability, low hygroscopicity and low moisture content over others and thus boost the segment growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Growing geriatric population with increasing allergic patients, high public and private healthcare spending are stimulating the growth of the region. As per the Centers for Disease control and prevention, an estimated 50 million Americans suffer from allergies each year and allergies are the 6th leading cause for chronic in the US, hence promote the revenue growth in this region.
Competitive Landscape
The Hydroxyimine Market is moderately competitive and consists of several global as well as local players.Some of the companies which are currently dominating the market are Teva Pharmaceuticals, Pfizer, GlaxoSmithKline, Alliance Pharma, Piramal Healthcare UK Limited.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Population with Allergic Reaction
4.2.2 Rise in Geriatric Population
4.2.3 Increasing Prevalence of Anxiety Disorders
4.3 Market Restraints
4.3.1 Side Effects associated with the Medication
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Dosage Form
5.1.1 Tablets
5.1.2 Capsules
5.1.3 Injection
5.1.4 Syrup
5.2 By Indication Type
5.2.1 Histamine-Mediated Pruritus
5.2.2 Urticaria
5.2.3 Atopic Contact Dermatoses
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceuticals
6.1.2 Pfizer
6.1.3 GlaxoSmithKline
6.1.4 Alliance Pharma
6.1.5 Piramal Healthcare UK Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS